PT Kalbe Farma Tbk Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2011; Provides Earnings Guidance for the Year 2012
March 29, 2012
Share
PT Kalbe Farma Tbk reported audited consolidated earnings results for the year ended December 31, 2011. For the period, the company reported consolidated net profit of IDR 1.48 trillion an increase of approximately 15.2% compared to IDR 1.28 trillion net profits in the previous year. Earnings per share increased by approximately 15.2%, to IDR 158 per share from IDR 137 per share. Net sales of IDR 10.91 trillion up by 6.7% compared to IDR 10.22 trillion a year ago.
In 2012, the company targets to achieve sales growth of 18% - 20%, with operating profit margin of approximately 16.0% - 16.5%. Earnings per share is forecasted to range from IDR 173 to IDR 180 per share, reflecting an increase of 10% - 15% compared to 2011.
PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.
PT KALBE FARMA TBK. 
